Document is current
Any future updates will be listed below
-
Authors
Roy, Payel https://orcid.org/0000-0003-2511-068X
Bellapu, Anusha https://orcid.org/0000-0003-0605-1063
Suthahar, Sujit Silas Armstrong
Oliaeimotlagh, Mohammad
Lyu, Qingkang
Parashar, Smriti https://orcid.org/0000-0002-6348-2612
Makings, Jeffrey
Wu, Runpei
Kumar, Sunil
Mehta, Megh
Chiang, Austin W. T.
Sette, Alessandro https://orcid.org/0000-0001-7013-2250
McNamara, Coleen A. https://orcid.org/0000-0002-0049-9986
Ley, Klaus https://orcid.org/0000-0001-9339-3672
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (HL136275, HL145241)
- License Information
-
More Information
Article History
Received: 16 October 2024
Accepted: 13 May 2025
First Online: 18 June 2025
Competing interests
: K.L. is the founder and co-owner of Atherovax, Inc. He receives no compensation from Atherovax. No Atherovax funds were used in this study. K.L. and P.R. are named as co-inventors on a patent application (provisional application no. 63/789,764, filed by the La Jolla Institute for Immunology, approval status pending) that is related to the use of human APOB epitopes and related methods in modulating inflammatory responses and treating adverse cardiovascular events, disease and atherosclerosis. The other authors declare no competing interests.
